1
|
Leir SH, Tkachenko S, Paranjapye A, Meckler F, Van Wettere AJ, Kerschner JL, Kuznetsov E, Schacht M, Gillurkar P, Regouski M, Viotti Perisse I, Marriott CM, Liu Y, Bunderson I, White KL, Polejaeva IA, Harris A. Stellate cells are in utero markers of pancreatic disease in cystic fibrosis. Mol Med 2024; 30:115. [PMID: 39112965 PMCID: PMC11304907 DOI: 10.1186/s10020-024-00871-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2024] [Accepted: 06/28/2024] [Indexed: 08/11/2024] Open
Abstract
BACKGROUND Pancreatic fibrosis is an early diagnostic feature of the common inherited disorder cystic fibrosis (CF). Many people with CF (pwCF) are pancreatic insufficient from birth and the replacement of acinar tissue with cystic lesions and fibrosis is a progressive phenotype that may later lead to diabetes. Little is known about the initiating events in the fibrotic process though it may be a sequela of inflammation in the pancreatic ducts resulting from loss of CFTR impairing normal fluid secretion. Here we use a sheep model of CF (CFTR-/-) to examine the evolution of pancreatic disease through gestation. METHODS Fetal pancreas was collected at six time points from 50-days of gestation through to term, which is equivalent to ~ 13 weeks to term in human. RNA was extracted from tissue for bulk RNA-seq and single cells were prepared from 80-day, 120-day and term samples for scRNA-seq. Data were validated by immunochemistry. RESULTS Transcriptomic evidence from bulk RNA-seq showed alterations in the CFTR-/- pancreas by 65-days of gestation, which are accompanied by marked pathological changes by 80-days of gestation. These include a fibrotic response, confirmed by immunostaining for COL1A1, αSMA and SPARC, together with acinar loss. Moreover, using scRNA-seq we identify a unique cell population that is significantly overrepresented in the CFTR-/- animals at 80- and 120-days gestation, as are stellate cells at term. CONCLUSION The transcriptomic changes and cellular imbalance that we observe likely have pivotal roles in the evolution of CF pancreatic disease and may provide therapeutic opportunities to delay or prevent pancreatic destruction in CF.
Collapse
Affiliation(s)
- Shih-Hsing Leir
- Department of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, OH, 44106-4955, USA
| | - Svyatoslav Tkachenko
- Department of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, OH, 44106-4955, USA
| | - Alekh Paranjapye
- Department of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, OH, 44106-4955, USA
- Department of Genetics, University of Pennsylvania, Philadelphia, PA, USA
| | - Frederick Meckler
- Department of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, OH, 44106-4955, USA
| | - Arnaud J Van Wettere
- Department of Animal, Dairy and Veterinary Sciences, Utah State University, Logan, UT, USA
| | - Jenny L Kerschner
- Department of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, OH, 44106-4955, USA
| | - Elizabeth Kuznetsov
- Department of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, OH, 44106-4955, USA
| | - Makayla Schacht
- Department of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, OH, 44106-4955, USA
| | - Pulak Gillurkar
- Department of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, OH, 44106-4955, USA
| | - Misha Regouski
- Department of Animal, Dairy and Veterinary Sciences, Utah State University, Logan, UT, USA
| | - Iuri Viotti Perisse
- Department of Animal, Dairy and Veterinary Sciences, Utah State University, Logan, UT, USA
| | - Cheyenne M Marriott
- Department of Animal, Dairy and Veterinary Sciences, Utah State University, Logan, UT, USA
| | - Ying Liu
- Department of Animal, Dairy and Veterinary Sciences, Utah State University, Logan, UT, USA
| | - Ian Bunderson
- Department of Animal, Dairy and Veterinary Sciences, Utah State University, Logan, UT, USA
| | - Kenneth L White
- Department of Animal, Dairy and Veterinary Sciences, Utah State University, Logan, UT, USA
| | - Irina A Polejaeva
- Department of Animal, Dairy and Veterinary Sciences, Utah State University, Logan, UT, USA
| | - Ann Harris
- Department of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, OH, 44106-4955, USA.
| |
Collapse
|
2
|
Kahm YJ, Jung U, Kim RK. Regulation of Cancer Stem Cells and Epithelial-Mesenchymal Transition by CTNNAL1 in Lung Cancer and Glioblastoma. Biomedicines 2023; 11:biomedicines11051462. [PMID: 37239133 DOI: 10.3390/biomedicines11051462] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2023] [Revised: 04/26/2023] [Accepted: 05/12/2023] [Indexed: 05/28/2023] Open
Abstract
CTNNAL1 is a protein known to be involved in cell-cell adhesion and cell adhesion. Alterations in the expression or function of CTNNAL1 have been reported to contribute to the development and progression of various types of cancer. In breast cancer, CTNNAL1 has been reported as a cancer suppressor gene, and in melanoma and lung cancer, it has been reported as a cancer driver gene. However, due to a lack of research, its function remains unclear. In this study, it is shown that CTNNAL1 regulates cancer stem cells (CSCs) in lung cancer and glioblastoma and modulates their migration and invasion abilities. CSCs are known to play an important role in the malignant transformation of cancer. They have the ability to resist chemotherapeutic drugs and irradiation, which is a known obstacle to cancer treatment. We found that CTNNAL1 regulates the ability to resist irradiation. In addition, we observed that CTNNAL1 regulates the ability of cells to migrate and invade, a key feature of the epithelial to mesenchymal transition phenomenon associated with cancer metastasis. CTNNAL1 was also involved in the secretion of C-C motif chemokine ligand 2 (CCL2), one of the chemokines. CCL2 plays a role in the recruitment of immune cells to the tumor microenvironment, but in cancer, it is known to influence malignancy and metastasis. CTNNAL1 may be a novel target for treating lung CSCs and glioma stem cells and may be used as a marker of malignancy.
Collapse
Affiliation(s)
- Yeon-Jee Kahm
- Department of Radiation Biology, Environmental Safety Technology Research Division, Korea Atomic Energy Research Institute, Yuseong-Gu, Daejeon 34057, Republic of Korea
- Department of Radiation Life Science, University of Science and Technology, Yuseong-Gu, Daejeon 34057, Republic of Korea
| | - Uhee Jung
- Department of Radiation Biology, Environmental Safety Technology Research Division, Korea Atomic Energy Research Institute, Yuseong-Gu, Daejeon 34057, Republic of Korea
| | - Rae-Kwon Kim
- Department of Radiation Biology, Environmental Safety Technology Research Division, Korea Atomic Energy Research Institute, Yuseong-Gu, Daejeon 34057, Republic of Korea
- Department of Radiation Life Science, University of Science and Technology, Yuseong-Gu, Daejeon 34057, Republic of Korea
| |
Collapse
|
3
|
The amyloid precursor protein binds to β-catenin and modulates its cellular distribution. Neurosci Lett 2018; 685:190-195. [DOI: 10.1016/j.neulet.2018.08.044] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2018] [Revised: 08/20/2018] [Accepted: 08/29/2018] [Indexed: 11/18/2022]
|
4
|
Tan M, Liu C, Huang W, Deng L, Qin X, Xiang Y. CTNNAL1 inhibits ozone-induced epithelial-mesenchymal transition in human bronchial epithelial cells. Exp Physiol 2018; 103:1157-1169. [PMID: 29791759 DOI: 10.1113/ep086839] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2017] [Accepted: 05/14/2018] [Indexed: 12/16/2022]
Abstract
NEW FINDINGS What is the central question of this study? What is the effect of catenin alpha-like 1 (CTNNAL1), an asthma-related epithelial adhesion molecule that plays a vital role in airway epithelial wound repair, on airway epithelial-mesenchymal transition? What is the main finding and its importance? CTNNAL1 inhibits ozone-induced airway epithelial-mesenchymal transition features, mediated by repressing the expression of Twist1 mRNA and reducing TGF-β1 levels. These findings contribute to our understanding of the pathology of airway EMT and may indicate a possible therapeutic target for airway remodelling in bronchial asthma. ABSTRACT Epithelial-mesenchymal transition (EMT), a crucial event occurring during epithelial and mesenchymal repair, was reported to be a possible mechanism for airway remodelling. Our previous work showed that the expression of catenin alpha-like 1 (CTNNAL1) was down-regulated in the bronchial epithelial cells of asthmatic models and played a vital role in airway epithelial wound repair. The aim of this study was to investigate the effect of CTNNAL1 on airway EMT. Overexpression or silencing of CTNNAL1 in human bronchial epithelial cells was induced by stable transfection. CTNNAL1 was silenced in primary mouse airway epithelial cells with an effective siRNA vector. Cells were stressed by ozone for 4 days at 30 min day-1 to induce EMT. EMT features, changes in the function of co-cultured lung fibroblasts, changes in the expression of the transcriptional repressors Snail/Slug and Twist1/Twist2 and changes in the secretion of transforming growth factor β1 (TGF-β1) were assayed in different cell lines with or without ozone exposure. Both ozone exposure and silencing of CTNNAL1 induced EMT features in airway epithelial cells. Functional changes in lung fibroblasts increased after co-culture with (ozone-stressed) CTNNAL1-silenced cells. Snail and Twist1 expression increased, and the level of TGF-β1 was enhanced. Conversely, CTNNAL1 overexpression reversed EMT features, repressed mRNA levels of Twist1 and reduced the secretion of TGF-β1, both alone and in combination with ozone exposure. Our results indicate that ozone exposure induces airway EMT and that CTNNAL1 inhibits ozone-induced airway EMT. CTNNAL1 may play a role in airway EMT by repressing the expression of Twist1 mRNA and reducing the level of TGF-β1.
Collapse
Affiliation(s)
- Meiling Tan
- School of Basic Medicine, Central South University, Changsha, Hunan, 410078, China
| | - Caixia Liu
- School of Basic Medicine, Central South University, Changsha, Hunan, 410078, China
| | - Wenjie Huang
- School of Basic Medicine, Central South University, Changsha, Hunan, 410078, China
| | - Linhong Deng
- Changzhou Key Laboratory of Respiratory Medical Engineering, Institute of Biomedical Engineering and Health Sciences, Changzhou, Jiangsu, 213164, China
| | - Xiaoqun Qin
- School of Basic Medicine, Central South University, Changsha, Hunan, 410078, China
| | - Yang Xiang
- School of Basic Medicine, Central South University, Changsha, Hunan, 410078, China
| |
Collapse
|
5
|
Bear MD, Liu T, Abualkhair S, Ghamloush MA, Hill NS, Preston I, Fanburg BL, Kayyali US, Toksoz D. Alpha-Catulin Co-Localizes With Vimentin Intermediate Filaments and Functions in Pulmonary Vascular Endothelial Cell Migration via ROCK. J Cell Physiol 2015; 231:934-43. [PMID: 26377600 DOI: 10.1002/jcp.25185] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2015] [Accepted: 09/03/2015] [Indexed: 01/01/2023]
Abstract
The ubiquitous α-catulin acts as a scaffold for distinct signalosomes including RhoA/ROCK; however, its function is not well understood. While α-catulin has homology to the cytoskeletal linkers α-catenin and vinculin, it appears to be functionally divergent. Here we further investigated α-catulin function in pulmonary vascular endothelial cells (VEC) on the premise that α-catulin has a unique cytoskeletal role. Examination of endogenous α-catulin intracellular localization by immunofluorescence revealed a highly organized cytosolic filamentous network suggestive of a cytoskeletal system in a variety of cultured VEC. Double-immunofluorescence analyses of VEC showed endogenous α-catulin co-localization with vimentin intermediate filaments. Similar to vimentin, α-catulin was found to distribute into detergent-soluble and -insoluble fractions. Treatment of VEC with withaferinA, an agent that targets vimentin filaments, disrupted the α-catulin network distribution and altered α-catulin solubility. Vimentin participates in cell migration, and withaferinA was found to inhibit VEC migration in vitro; similarly, α-catulin knock-down reduced VEC migration. Based on previous reports showing that ROCK modulates vimentin, we found that ROCK depletion attenuated VEC migration; furthermore, α-catulin depletion was shown to reduce ROCK-induced signaling. These findings indicate that α-catulin has a unique function in co-localization with vimentin filaments that contributes to VEC migration via a pathway that may involve ROCK signaling. J. Cell. Physiol. 231: 934-943, 2016. © 2015 Wiley Periodicals, Inc.
Collapse
Affiliation(s)
- Michael D Bear
- Division of Pulmonary, Critical Care and Sleep, Tupper Research Institute, Tufts Medical Center, Tufts University School of Medicine, Boston, Massachusetts
| | - Tiegang Liu
- Division of Pulmonary, Critical Care and Sleep, Tupper Research Institute, Tufts Medical Center, Tufts University School of Medicine, Boston, Massachusetts
| | - Shereen Abualkhair
- Division of Pulmonary, Critical Care and Sleep, Tupper Research Institute, Tufts Medical Center, Tufts University School of Medicine, Boston, Massachusetts
| | | | - Nicholas S Hill
- Division of Pulmonary, Critical Care and Sleep, Tupper Research Institute, Tufts Medical Center, Tufts University School of Medicine, Boston, Massachusetts
| | - Ioana Preston
- Division of Pulmonary, Critical Care and Sleep, Tupper Research Institute, Tufts Medical Center, Tufts University School of Medicine, Boston, Massachusetts
| | - Barry L Fanburg
- Division of Pulmonary, Critical Care and Sleep, Tupper Research Institute, Tufts Medical Center, Tufts University School of Medicine, Boston, Massachusetts
| | - Usamah S Kayyali
- Division of Pulmonary, Critical Care and Sleep, Tupper Research Institute, Tufts Medical Center, Tufts University School of Medicine, Boston, Massachusetts
| | - Deniz Toksoz
- Division of Pulmonary, Critical Care and Sleep, Tupper Research Institute, Tufts Medical Center, Tufts University School of Medicine, Boston, Massachusetts
| |
Collapse
|
6
|
The upregulated α-catulin expression was involved in head-neck squamous cell carcinogenesis by promoting proliferation, migration, invasion, and epithelial to mesenchymal transition. Tumour Biol 2015; 37:1671-81. [DOI: 10.1007/s13277-015-3901-5] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2015] [Accepted: 08/05/2015] [Indexed: 10/23/2022] Open
|
7
|
Kopf S, Viola K, Atanasov AG, Jarukamjorn K, Rarova L, Kretschy N, Teichmann M, Vonach C, Saiko P, Giessrigl B, Huttary N, Raab I, Krieger S, Schumacher M, Diederich M, Strnad M, de Martin R, Szekeres T, Jäger W, Dirsch VM, Mikulits W, Grusch M, Dolznig H, Krupitza G. In vitro characterisation of the anti-intravasative properties of the marine product heteronemin. Arch Toxicol 2013; 87:1851-61. [DOI: 10.1007/s00204-013-1045-1] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2012] [Accepted: 03/19/2013] [Indexed: 10/27/2022]
|
8
|
Xanthohumol attenuates tumour cell-mediated breaching of the lymphendothelial barrier and prevents intravasation and metastasis. Arch Toxicol 2013; 87:1301-12. [DOI: 10.1007/s00204-013-1028-2] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2012] [Accepted: 02/25/2013] [Indexed: 01/09/2023]
|
9
|
Cao C, Chen Y, Masood R, Sinha UK, Kobielak A. α-Catulin marks the invasion front of squamous cell carcinoma and is important for tumor cell metastasis. Mol Cancer Res 2012; 10:892-903. [PMID: 22648798 DOI: 10.1158/1541-7786.mcr-12-0169] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Squamous cell carcinomas (SCC) comprise the most common types of human epithelial cancers. One subtype, head and neck squamous cell carcinoma (HNSCC), is a particularly aggressive cancer with poor prognosis due to late diagnosis and lymph node metastasis. Of all the processes involved in carcinogenesis, local invasion and distant metastasis are clinically the most relevant, but are the least well understood on a molecular level. Here, we find that in vivo, the α-catenin homologue-α-catulin, a protein originally reported to interact with Lbc Rho guanine nucleotide exchange factor, is highly expressed at the tumor invasion front and in the metastatic streams of cells in both malignant hHNSCCs and a mouse model of oral SCC. Knockdown of α-catulin in hHNSCC cell lines dramatically decrease the migratory and invasive potential of those cells in vitro and metastatic potential in xenotransplants in vivo. Analysis of tumors deficient in α-catulin showed that the tumor cells are unable to invade the surrounding stroma. Accordingly, transcriptional profiling of those tumors revealed that α-catulin ablation is accompanied by changes in genes involved in cell migration and invasion. Interestingly enough, in vitro experiments show that an upregulation of α-catulin expression correlates with the transition of tumor cells from an epithelial to a mesenchymal morphology, as well as an upregulation of epithelial-to-mesenchymal transition (EMT) markers vimentin and snail. Overall, these results strongly indicate that α-catulin contributes to the invasive behavior of metastatic cells and may be used as a prognostic marker and future therapeutic target for patients with cancer.
Collapse
Affiliation(s)
- Christine Cao
- Department of Otolaryngology and Biochemistry and Molecular Biology, Norris Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
| | | | | | | | | |
Collapse
|
10
|
Xiang Y, Qin XQ, Liu HJ, Tan YR, Liu C, Liu CX. Identification of transcription factors regulating CTNNAL1 expression in human bronchial epithelial cells. PLoS One 2012; 7:e31158. [PMID: 22359570 PMCID: PMC3281047 DOI: 10.1371/journal.pone.0031158] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2011] [Accepted: 01/03/2012] [Indexed: 11/18/2022] Open
Abstract
Adhesion molecules play important roles in airway hyperresponsiveness or airway inflammation. Our previous study indicated catenin alpha-like 1 (CTNNAL1), an alpha-catenin-related protein, was downregulated in asthma patients and animal model. In this study, we observed that the expression of CTNNAL1 was increased in lung tissue of the ozone-stressed Balb/c mice model and in acute ozone stressed human bronchial epithelial cells (HBEC). In order to identify the possible DNA-binding proteins regulating the transcription of CTNNAL1 gene in HBEC, we designed 8 oligo- nucleotide probes corresponding to various regions of the CTNNAL1 promoter in electrophoretic mobility shift assays (EMSA). We detected 5 putative transcription factors binding sites within CTNNAL1 promoter region that can recruit LEF-1, AP-2α and CREB respectively by EMSA and antibody supershift assay. Chromatin immunoprecipitation (ChIP) assay verified that AP-2 α and LEF-1 could be recruited to the CTNNAL1 promoter. Therefore we further analyzed the functions of putative AP-2 and LEF-1 sites within CTNNAL1 promoter by site-directed mutagenesis of those sites within pGL3/FR/luc. We observed a reduction in human CTNNAL1 promoter activity of mutants of both AP-2α and LEF-1 sites. Pre-treatment with ASOs targeting LEF-1and AP-2α yielded significant reduction of ozone-stress-induced CTNNAL1 expression. The activation of AP-2α and LEF-1, followed by CTNNAL1 expression, showed a correlation during a 16-hour time course. Our data suggest that a robust transcriptional CTNNAL1 up-regulation occurs during acute ozone-induced stress and is mediated at least in part by ozone-induced recruitments of LEF-1 and AP-2α to the human CTNNAL1 promoter.
Collapse
Affiliation(s)
- Yang Xiang
- Xiangya School of Medicine, Central South University, Changsha, Hunan, China
| | - Xiao-Qun Qin
- Xiangya School of Medicine, Central South University, Changsha, Hunan, China
- * E-mail:
| | - Hui-Jun Liu
- Xiangya School of Medicine, Central South University, Changsha, Hunan, China
| | - Yu-Rong Tan
- Xiangya School of Medicine, Central South University, Changsha, Hunan, China
| | - Chi Liu
- Xiangya School of Medicine, Central South University, Changsha, Hunan, China
| | - Cai-Xia Liu
- Xiangya School of Medicine, Central South University, Changsha, Hunan, China
| |
Collapse
|
11
|
Fan LC, Chiang WF, Liang CH, Tsai YT, Wong TY, Chen KC, Hong TM, Chen YL. α-Catulin knockdown induces senescence in cancer cells. Oncogene 2011; 30:2610-21. [PMID: 21278790 DOI: 10.1038/onc.2010.637] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Cellular senescence functions as a tumor suppressor that protects against cancer progression. α-Catulin, an α-catenin-related protein, is reported to have tumorigenic potential because it regulates the nuclear factor-κB (NF-κB) pathway, but little is known about its clinical relevance and the mechanism through which it regulates cancer progression. Here, we found that α-catulin mRNA levels were significantly upregulated in cancer cell lines and clinical oral squamous cell carcinomas, which positively correlated with tumor size (P=0.001) and American Joint Committee on Cancer (AJCC) stage (P=0.004). α-Catulin knockdown in the OC2 and A549 cancer cell lines dramatically decreased cell proliferation and contributed to cellular senescence, and inhibited OC2 xenograft growth. Mechanistic dissection showed that α-catulin depletion strongly induced the DNA-damage response (DDR) in both cell lines, via a p53/p21-dependent pathway in A549 cells, but a p53/p21-independent pathway in OC2 cells carrying mutant p53. Global gene expression analysis revealed that α-catulin knockdown altered cell-cycle regulation and DDR pathways at the presenescent stage as well as significantly downregulate several crucial genes related to mitotic chromosome condensation, DDR and DNA repair systems, which suggests that its depletion-induced cellular senescence might be caused by chromosome condensation failures, severe DNA damage and impaired DNA repair ability. Our study provides evidence that α-catulin promotes tumor growth by preventing cellular senescence and suggests that downregulating α-catulin may be a promising therapeutic approach for cancer treatment.
Collapse
Affiliation(s)
- L-C Fan
- Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan, ROC
| | | | | | | | | | | | | | | |
Collapse
|
12
|
Bear MD, Li M, Liu Y, Giel-Moloney MA, Fanburg BL, Toksoz D. The Lbc Rho guanine nucleotide exchange factor α-catulin axis functions in serotonin-induced vascular smooth muscle cell mitogenesis and RhoA/ROCK activation. J Biol Chem 2010; 285:32919-32926. [PMID: 20696764 DOI: 10.1074/jbc.m109.062513] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Serotonin (5-hydroxytryptamine, 5-HT) is mitogenic for several cell types including pulmonary arterial smooth muscle cells (PASMC), and is associated with the abnormal vascular smooth muscle remodeling that occurs in pulmonary arterial hypertension. RhoA/Rho kinase (ROCK) function is required for 5-HT-induced PASMC mitogenesis, and 5-HT activates RhoA; however, the signaling steps are poorly defined. Rho guanine nucleotide exchange factors (Rho GEFs) transduce extracellular signals to Rho, and we found that 5-HT treatment of PASMC led to increased membrane-associated Lbc Rho GEF, suggesting modulation by 5-HT. Lbc knockdown by siRNA attenuated 5-HT-induced thymidine uptake in PASMC, indicating a role in PASMC mitogenesis. 5-HT triggered Rho-dependent serum response factor-mediated reporter activation in PASMC, and this was reduced by Lbc depletion. Lbc knockdown reduced 5-HT-induced RhoA/ROCK activation, but not p42/44 ERK MAP kinase activation, suggesting that Lbc is an intermediary between 5-HT and RhoA/ROCK, but not ERK. 5-HT stimulation of PASMC led to increased association between Lbc, RhoA, and the α-catulin scaffold. Furthermore, α-catulin knockdown attenuated 5-HT-induced PASMC thymidine uptake. 5-HT-induced PASMC mitogenesis was reduced by dominant-negative G(q) protein, suggesting cooperation with Lbc/α-catulin. These results for the first time define a Rho GEF involved in vascular smooth muscle cell growth and serotonin signaling, and suggest that Lbc Rho GEF family members play distinct roles. Thus, the Lbc/α-catulin axis participates in 5-HT-induced PASMC mitogenesis and RhoA/ROCK signaling, and may be an interventional target in diseases involving vascular smooth muscle remodeling.
Collapse
Affiliation(s)
- Michael D Bear
- From the Division of Pulmonary and Critical Care, Tupper Research Institute, Tufts Medical Center, Boston, Massachusetts 02111
| | - Min Li
- From the Division of Pulmonary and Critical Care, Tupper Research Institute, Tufts Medical Center, Boston, Massachusetts 02111
| | - Yinglin Liu
- From the Division of Pulmonary and Critical Care, Tupper Research Institute, Tufts Medical Center, Boston, Massachusetts 02111
| | - Maryann A Giel-Moloney
- Department of Physiology, Tufts University School of Medicine, Boston, Massachusetts 02111
| | - Barry L Fanburg
- From the Division of Pulmonary and Critical Care, Tupper Research Institute, Tufts Medical Center, Boston, Massachusetts 02111
| | - Deniz Toksoz
- From the Division of Pulmonary and Critical Care, Tupper Research Institute, Tufts Medical Center, Boston, Massachusetts 02111.
| |
Collapse
|
13
|
Xiang Y, Tan YR, Zhang JS, Qin XQ, Hu BB, Wang Y, Qu F, Liu HJ. Wound repair and proliferation of bronchial epithelial cells regulated by CTNNAL1. J Cell Biochem 2008; 103:920-30. [PMID: 17647259 DOI: 10.1002/jcb.21461] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Adhesion molecules play vital roles in airway hyperresponsiveness (AHR) or airway inflammation. Our previous study indicated that adhesion molecule catenin alpha-like 1 (CTNNAL1) is relevant closely to asthma susceptibility, but its biological function or significance is still unclear. In the present study, we observed the temporal and spatial distribution of CTNNAL1 expression in mouse lung tissue with the OVA-sensitized asthma model and found that the level of CTNNAL1 mRNA showed a prominent negative correlation with pulmonary resistance (R(L)). To study the function of CTNNAL1 in airway, effects of CTNNAL1 on proliferation and wound repair activity of human bronchial epithelial cells (HBEC) was investigated with antisense oligonucleotide (ASO) technique. The results showed that: (1) CTNNAL1 ASO could decelerate the repairing velocity and proliferation of HBEC; (2) CTNNAL1 expression was increased on the edge cells of mechanic wounded area in culture; (3) extracellular matrix component fibronectin (Fn) obviously promoted wound repair activity and proliferation of HBEC, which could be blocked by CTNNAL1 ASO; (4) Western blot showed that Fn could promote FAK phosphorylation, which also be inhibited by CTNNAL1 ASO. In conclusion, the level of CTNNAL1 mRNA expression is highly correlated to airway resistance; CTNNAL1 may contribute to the wound repair and proliferation of HBEC. Furthermore, it may serve to Fn mediated cell-extracellular adhesion and its signal transduction.
Collapse
Affiliation(s)
- Yang Xiang
- Xiangya School of Medicine, Central South University, Changsha 410078, Hunan, PR China
| | | | | | | | | | | | | | | |
Collapse
|
14
|
Merdek KD, Jaffe AB, Dutt P, Olson MF, Hall A, Fanburg BL, Kayyali US, Toksoz D. Alpha(E)-Catenin induces SRF-dependent transcriptional activity through its C-terminal region and is partly RhoA/ROCK-dependent. Biochem Biophys Res Commun 2007; 366:717-23. [PMID: 18078809 DOI: 10.1016/j.bbrc.2007.12.012] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2007] [Accepted: 12/02/2007] [Indexed: 11/30/2022]
Abstract
The ubiquitous alpha(E)-catenin is an essential actin cytoskeletal linker. The transcription factor, serum response factor (SRF), induces transcription via binding to the serum response element (SRE) in gene promoters, and in many cases responds to actin dynamics. Here, we report that alpha(E)-catenin expression in HEK293 cells activates the SRE.L transcriptional reporter, a reporter containing the isolated SRF-binding site, and a stably integrated SRE.L reporter in fibroblasts. alpha-Catenin-induced reporter activity appears only partly dependent on RhoA GTPase and Rho kinase function. alpha-Catenin expression has no effect on RhoA activation or localization, and alpha-catenin-induced SRE.L reporter activation is insensitive to the actin-modulating agent latrunculin B. Ectopic alpha-catenin expression was not sufficient to induce actin filament assembly as measured by stress fiber formation. SRE.L reporter is activated by the C-terminal approximately 300 residue region of alpha(E)-catenin. These results suggest induction of SRF-mediated transcription by alpha(E)-catenin either downstream of RhoA or via a parallel pathway.
Collapse
Affiliation(s)
- Keith D Merdek
- Physiology Department, Tufts University School of Medicine, Boston, MA 02111, USA
| | | | | | | | | | | | | | | |
Collapse
|
15
|
Wiesner C, Winsauer G, Resch U, Hoeth M, Schmid JA, van Hengel J, van Roy F, Binder BR, de Martin R. Alpha-catulin, a Rho signalling component, can regulate NF-kappaB through binding to IKK-beta, and confers resistance to apoptosis. Oncogene 2007; 27:2159-69. [PMID: 17952117 DOI: 10.1038/sj.onc.1210863] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Rho GTPases regulate diverse cellular functions including adhesion, cytokinesis and motility, as well as the activity of the transcription factors NF-kappaB, serum response factor and C/EBP. alpha-Catulin, an alpha-catenin-related protein that shares structural similarities with cytoskeletal linker proteins, facilitates Rho signalling by serving as a scaffold for the Rho-specific guanine nucleotide exchange factor Lbc. We report here that alpha-catulin also interacts with a key component of the NF-kappaB signalling pathway, namely the IkappaB kinase (IKK)-beta. In co-immunoprecipitations, alpha-catulin can bind IKK-beta and Lbc. Ectopic expression of alpha-catulin augmented NF-kappaB activity, promoted cell migration and increased resistance to apoptosis, whereas knockdown experiments showed the opposite effects. Together, these features suggest that alpha-catulin has tumorigenic potential.
Collapse
Affiliation(s)
- C Wiesner
- Department of Vascular Biology and Thrombosis Research, Medical University of Vienna, Vienna, Austria
| | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Zhang JS, Gong A, Cheville JC, Smith DI, Young CYF. AGR2, an androgen-inducible secretory protein overexpressed in prostate cancer. Genes Chromosomes Cancer 2005; 43:249-59. [PMID: 15834940 DOI: 10.1002/gcc.20188] [Citation(s) in RCA: 114] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
AGR2, the human homologue of Xenopus anterior gradient 2 (XAG2), was identified by a suppression subtractive hybridization-based technique as an androgen-inducible gene. There are two AGR2 transcripts, which encode the same secretory protein of 175 amino acids. The androgen induction was time- and dose-dependent, with more than a 10-fold increase in the level of AGR2 mRNA after 48 hr of treatment with 10(-9) M R1881. Expression of AGR2 mRNA was specifically detected in limited human tissue rich in epithelial cells, including the prostate gland. Analysis of 46 microdissected primary prostate adenocarcinoma samples showed that AGR2 mRNA expression was markedly elevated in the majority of tumors as compared to matched adjacent benign tissues. Androgen-induced AGR2 protein expression was demonstrated in LNCaP cells by Western blot analysis with an anti-AGR2 antibody. Immunohistochemistry analysis indicated that AGR2 protein expression was highly restricted to the secretory epithelial cells in the prostate gland. In tissue sections from radical prostatectomy specimens, immunohistochemical staining of AGR2 showed markedly increased expression in high-grade prostatic intraepithelial neoplasia and Gleason pattern 3-4 prostatic adenocarcinoma. Therefore, the androgen-induced secretory protein AGR2 may serve as a potential therapeutic target and/or molecular marker for prostate cancer.
Collapse
Affiliation(s)
- Jin-San Zhang
- Department of Urology, Mayo Clinic College of Medicine, Mayo Clinic/Foundation, Rochester, MN 55905, USA
| | | | | | | | | |
Collapse
|
17
|
Kobielak A, Fuchs E. Alpha-catenin: at the junction of intercellular adhesion and actin dynamics. Nat Rev Mol Cell Biol 2004; 5:614-25. [PMID: 15366705 PMCID: PMC2475680 DOI: 10.1038/nrm1433] [Citation(s) in RCA: 255] [Impact Index Per Article: 12.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
Alpha-catenin has often been considered to be a non-regulatory intercellular adhesion protein, in contrast to beta-catenin, which has well-documented dual roles in cell-cell adhesion and signal transduction. Recently, however, alpha-catenin has been found to be important not only in connecting the E-cadherin-beta-catenin complex to the actin cytoskeleton, but also in coordinating actin dynamics and inversely correlating cell adhesion with proliferation. As the number of alpha-catenin-interacting partners increases, intriguing new connections imply even more complex regulatory functions for this protein.
Collapse
Affiliation(s)
- Agnieszka Kobielak
- Howard Hughes Medical Institute, Laboratory of Mammalian Cell Biology and Development, Rockefeller University, 1230 York Avenue, Box 300, New York, New York 10021, USA
| | | |
Collapse
|
18
|
Merdek KD, Nguyen NT, Toksoz D. Distinct activities of the alpha-catenin family, alpha-catulin and alpha-catenin, on beta-catenin-mediated signaling. Mol Cell Biol 2004; 24:2410-22. [PMID: 14993280 PMCID: PMC355851 DOI: 10.1128/mcb.24.6.2410-2422.2004] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Alpha-catenin, an integral part of cadherin-catenin adhesion complexes, is a major binding partner of beta-catenin, a key component of the Wnt pathway, which activates T-cell factor (TCF)/lymphoid enhancer factor (LEF) transcription and is often upregulated in cancers. Recently, we identified an alpha-catenin-related protein, alpha-catulin, whose function is poorly understood, as part of a Rho GTPase signaling complex. Here, based on evidence suggesting that alpha-catulin may associate with a beta-catenin fraction, we investigated the role of alpha-catenin family members in beta-catenin-mediated signals. Expression of the full length or a 103-residue region of alpha-catenin strongly inhibits the induction of the TCF/LEF-responsive TOPFLASH reporter in HEK293T cells expressing activated beta-catenin or in cancer cells with constitutively upregulated Wnt signaling, whereas alpha-catulin expression had no effect. Interestingly, alpha-catulin expression attenuates the activation of the cyclin D1 promoter, a target of Wnt pathway signals. Alpha-catulin appears to inhibit Ras-mediated signals to the cyclin D1 promoter, rather than beta-catenin signals, and the synergy between Ras and beta-catenin required to fully activate this promoter. Data suggesting the involvement of Rho in this response are presented and discussed. These results suggest a novel function for alpha-catulin and imply that alpha-catenin and alpha-catulin have distinct activities that downregulate, respectively, beta-catenin and Ras signals converging on the cyclin D1 promoter.
Collapse
Affiliation(s)
- Keith D Merdek
- Department of Physiology, Tufts University School of Medicine, Boston, Massachusetts 02111, USA.
| | | | | |
Collapse
|
19
|
Bourdeau I, Antonini SR, Lacroix A, Kirschner LS, Matyakhina L, Lorang D, Libutti SK, Stratakis CA. Gene array analysis of macronodular adrenal hyperplasia confirms clinical heterogeneity and identifies several candidate genes as molecular mediators. Oncogene 2004; 23:1575-85. [PMID: 14767469 DOI: 10.1038/sj.onc.1207277] [Citation(s) in RCA: 92] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Corticotropin (ACTH)-independent macronodular adrenal hyperplasia (AIMAH) is a heterogeneous condition in which cortisol secretion may be mediated by gastrointestinal peptide (GIP), vasopressin, catecholamines and other hormones. We studied the expression profile of AIMAH by genomic cDNA microarray analysis. Total RNA was extracted from eight tissues (three GIP-dependent) and compared to total RNA obtained from adrenal glands from 62 normal subjects. Genes had to be altered in 75% of the patients, and be up- or downregulated at a cutoff ratio of at least 2.0; 82 and 31 genes were found to be consistently up- and downregulated, respectively. Among the former were regulators of transcription, chromatin remodeling, and cell cycle and adhesion. Downregulated sequences included genes involved in immune responses and insulin signaling. Hierarchical clustering correlated with the two main AIMAH diagnostic groups: GIP-dependent and non-GIP-dependent. The genes encoding the 7B2 protein (SGNE1) and WNT1-inducible signaling pathway protein 2 (WISP2) were specifically overexpressed in the GIP-dependent AIMAH. For these, and six more genes, the data were validated by semiquantitative amplification in samples from a total of 32 patients (the original eight, six more cases of AIMAH, and 18 other adrenocortical hyperplasias and tumors) and the H295R adrenocortical cancer cell line. In conclusion, our data confirmed AIMAH's clinical heterogeneity by identifying molecularly distinct diagnostic subgroups. Several candidate genes that may be responsible for AIMAH formation and/or progression were also identified, suggesting pathways that affect the cell cycle, adhesion and transcription as possible mediators of adrenocortical hyperplasia.
Collapse
Affiliation(s)
- Isabelle Bourdeau
- Section on Endocrinology & Genetics, Developmental Endocrinology Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892, USA
| | | | | | | | | | | | | | | |
Collapse
|
20
|
Chung KW, Ferrell RE, Ellis D, Barmada M, Moritz M, Finegold DN, Jaffe R, Vats A. African American hypertensive nephropathy maps to a new locus on chromosome 9q31-q32. Am J Hum Genet 2003; 73:420-9. [PMID: 12840782 PMCID: PMC1180380 DOI: 10.1086/377184] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2003] [Accepted: 05/28/2003] [Indexed: 12/17/2022] Open
Abstract
Hypertensive nephropathy (HN) and focal segmental glomerulosclerosis (FSGS) are significant causes of end-stage renal disease (ESRD), but no genes or loci have been associated with this phenotype among African Americans, a group at high risk. We performed a genomewide linkage scan with approximately 400 microsatellite markers on 23 individuals of a large four-generation African American family with 18 affected individuals (7 with ESRD), in which the 13-year-old proband (also with ESRD) presented with hypertension and proteinuria (2-4 g/day) and underwent a kidney biopsy that revealed FSGS-like lesions with arteriolar thickening. A genomewide scan revealed LOD scores of >2.5 for markers on chromosomes 3 and 9, and fine mapping was performed on 5 additional members (total 28 members) that showed a maximum multipoint LOD score of 5.4 in the 9q31-q32 region, under an autosomal dominant model with 99% penetrance. This 8-cM (6-Mb) region is flanked by markers D9S172 and D9S105, and further candidate gene sequencing studies excluded the coding regions of three genes (ACTL7A, ACTL7B, and CTNNAL1). To our knowledge, this is the first report of a locus, denoted as "HNP1," for the HN/FSGS phenotype in a large African American family with dominantly inherited nephropathy characterized by ESRD, hypertension, and some features of FSGS.
Collapse
Affiliation(s)
- Ki Wha Chung
- Departments of Pediatrics and Pathology, Children’s Hospital of Pittsburgh, University of Pittsburgh School of Medicine, and Department of Human Genetics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh
| | - Robert E. Ferrell
- Departments of Pediatrics and Pathology, Children’s Hospital of Pittsburgh, University of Pittsburgh School of Medicine, and Department of Human Genetics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh
| | - Demetrius Ellis
- Departments of Pediatrics and Pathology, Children’s Hospital of Pittsburgh, University of Pittsburgh School of Medicine, and Department of Human Genetics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh
| | - Michael Barmada
- Departments of Pediatrics and Pathology, Children’s Hospital of Pittsburgh, University of Pittsburgh School of Medicine, and Department of Human Genetics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh
| | - Michael Moritz
- Departments of Pediatrics and Pathology, Children’s Hospital of Pittsburgh, University of Pittsburgh School of Medicine, and Department of Human Genetics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh
| | - David N. Finegold
- Departments of Pediatrics and Pathology, Children’s Hospital of Pittsburgh, University of Pittsburgh School of Medicine, and Department of Human Genetics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh
| | - Ronald Jaffe
- Departments of Pediatrics and Pathology, Children’s Hospital of Pittsburgh, University of Pittsburgh School of Medicine, and Department of Human Genetics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh
| | - Abhay Vats
- Departments of Pediatrics and Pathology, Children’s Hospital of Pittsburgh, University of Pittsburgh School of Medicine, and Department of Human Genetics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh
| |
Collapse
|
21
|
Park B, Nguyen NT, Dutt P, Merdek KD, Bashar M, Sterpetti P, Tosolini A, Testa JR, Toksoz D. Association of Lbc Rho guanine nucleotide exchange factor with alpha-catenin-related protein, alpha-catulin/CTNNAL1, supports serum response factor activation. J Biol Chem 2002; 277:45361-70. [PMID: 12270917 DOI: 10.1074/jbc.m202447200] [Citation(s) in RCA: 49] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
The Rho GTPase signaling pathway is required for actin cytoskeletal organization and serum response factor-dependent gene transcription. Lbc is a Rho-specific guanine nucleotide exchange factor that contains a modulatory C-terminal region. To elucidate Lbc regulatory mechanism(s), a yeast two-hybrid screen for proteins that interact with the Lbc C-terminal region was carried out, resulting in multiple isolation of cDNAs encoding the same 734-amino acid Lbc interacting protein. The Lbc interacting protein has homology with the alpha-catenin cell adhesion component and is identical to the alpha-catenin-like alpha-catulin protein of unknown function. The human alpha-catulin gene (CTNNAL1) maps to 9q31-32. Here we identify the predicted endogenous alpha-catulin product, document alpha-catulin and Lbc co-expression in multiple human cell lines, and show alpha-catulin and Lbc subcellular co-fractionation and intracellular localization. The required regions for Lbc and alpha-catulin interaction were mapped, and complex formation between Lbc and alpha-catulin in mammalian cells was detected. Functionally, alpha-catulin co-expression leads to increased Lbc-induced serum response factor activation in vivo as measured by a transcriptional reporter assay. Furthermore, alpha-catulin co-expression enhances Lbc-induced GTP-Rho formation in vivo. These results support the concept that the recently identified alpha-catulin protein may modulate Rho pathway signaling in vivo by providing a scaffold for the Lbc Rho guanine nucleotide exchange factor.
Collapse
Affiliation(s)
- Brian Park
- Department of Physiology, Tufts University School of Medicine, Boston, Massachusetts 02111, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Abstract
Familial dysautonomia is a severe autosomal-recessive neurodegenerative disease that primarily affects the Ashkenazi Jewish population. We present the mapping of alpha-catulin and show that it maps precisely to the familial dysautonomia candidate region on 9q31. Patient sequence analysis identified two new sequence variants, which show linkage disequilibrium with this disease. A G to A transition at nucleotide 423 in exon 3 is a silent base change that does not alter the Val residue at position 141. A G to C transversion at nucleotide 1579 changes the Glu at postion 527 to Gln. These base changes were analyzed in several patients, unaffected Ashkenazi Jewish controls, and non-Jewish controls. Because of the presence of these sequence variants in several unaffected individuals, alpha-catulin is unlikely to be the causative gene in this disease.
Collapse
Affiliation(s)
- P C Demacio
- Department of Genetics, Hospital for Sick Children, University of Toronto, ON, Canada
| | | |
Collapse
|
23
|
Simm M, Su Z, Huang EY, Chen Y, Jiang H, Volsky DJ, Fisher PB. Cloning of differentially expressed genes in an HIV-1 resistant T cell clone by rapid subtraction hybridization, RaSH. Gene 2001; 269:93-101. [PMID: 11376941 DOI: 10.1016/s0378-1119(01)00456-5] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
An HIV-1 resistant T cell clone R1c2 has been generated that carries mutant, latent HIV-1 in a minority of the cell population. Resistant cells express HIV-1 receptors CD4 and CXCR4 and display resistance to infection by wild type (wt) HIV-1 at the level of virus transcription. To begin to define the repertoire of genes modulated in R1c2 cells that correlate with and potentially control expression of the HIV-1 resistance phenotype we have employed a rapid subtraction hybridization (RaSH) technique. For this approach, cDNA libraries were prepared from double-stranded cDNAs that were enzymatically digested into small fragments, ligated to adapters, PCR amplified followed by incubation of tester and driver PCR fragments. The RaSH scheme resulted in the cloning of genes displaying differential expression between HIV-1 resistant (R1c2) and susceptible (SupT1) cells, including known genes and those not described in current DNA databases. Analysis of the pattern of expression of the differentially expressed genes documented eleven genes with enhanced (HR clones) and six genes with reduced (HS clones) expression in HIV-1 resistant versus HIV-1 susceptible T-cell clones.
Collapse
Affiliation(s)
- M Simm
- Molecular Virology Laboratory, St. Luke's-Roosevelt Hospital Center, Columbia University, New York, NY 10019, USA
| | | | | | | | | | | | | |
Collapse
|
24
|
Slaugenhaupt SA, Blumenfeld A, Gill SP, Leyne M, Mull J, Cuajungco MP, Liebert CB, Chadwick B, Idelson M, Reznik L, Robbins CM, Makalowska I, Brownstein MJ, Krappmann D, Scheidereit C, Maayan C, Axelrod FB, Gusella JF. Tissue-specific expression of a splicing mutation in the IKBKAP gene causes familial dysautonomia. Am J Hum Genet 2001; 68:598-605. [PMID: 11179008 PMCID: PMC1274473 DOI: 10.1086/318810] [Citation(s) in RCA: 423] [Impact Index Per Article: 18.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2000] [Accepted: 01/10/2001] [Indexed: 11/04/2022] Open
Abstract
Familial dysautonomia (FD; also known as "Riley-Day syndrome"), an Ashkenazi Jewish disorder, is the best known and most frequent of a group of congenital sensory neuropathies and is characterized by widespread sensory and variable autonomic dysfunction. Previously, we had mapped the FD gene, DYS, to a 0.5-cM region on chromosome 9q31 and had shown that the ethnic bias is due to a founder effect, with >99.5% of disease alleles sharing a common ancestral haplotype. To investigate the molecular basis of FD, we sequenced the minimal candidate region and cloned and characterized its five genes. One of these, IKBKAP, harbors two mutations that can cause FD. The major haplotype mutation is located in the donor splice site of intron 20. This mutation can result in skipping of exon 20 in the mRNA of patients with FD, although they continue to express varying levels of wild-type message in a tissue-specific manner. RNA isolated from lymphoblasts of patients is primarily wild-type, whereas only the deleted message is seen in RNA isolated from brain. The mutation associated with the minor haplotype in four patients is a missense (R696P) mutation in exon 19, which is predicted to disrupt a potential phosphorylation site. Our findings indicate that almost all cases of FD are caused by an unusual splice defect that displays tissue-specific expression; and they also provide the basis for rapid carrier screening in the Ashkenazi Jewish population.
Collapse
Affiliation(s)
- Susan A. Slaugenhaupt
- Molecular Neurogenetics Unit, Massachusetts General Hospital, Charlestown; Harvard Institute of Human Genetics, Harvard Medical School, Boston; Departments of Clinical Biochemistry and Pediatrics, Hadassah University Hospital, Jerusalem; Laboratory of Genetics, National Institute of Mental Health and National Human Genome Research Institute, and Genome Technology Branch, National Human Genome Research Institute, and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda; Max-Delbrück-Centrum for Molecular Medicine, Berlin; and Department of Pediatrics, New York University Medical Center, New York
| | - Anat Blumenfeld
- Molecular Neurogenetics Unit, Massachusetts General Hospital, Charlestown; Harvard Institute of Human Genetics, Harvard Medical School, Boston; Departments of Clinical Biochemistry and Pediatrics, Hadassah University Hospital, Jerusalem; Laboratory of Genetics, National Institute of Mental Health and National Human Genome Research Institute, and Genome Technology Branch, National Human Genome Research Institute, and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda; Max-Delbrück-Centrum for Molecular Medicine, Berlin; and Department of Pediatrics, New York University Medical Center, New York
| | - Sandra P. Gill
- Molecular Neurogenetics Unit, Massachusetts General Hospital, Charlestown; Harvard Institute of Human Genetics, Harvard Medical School, Boston; Departments of Clinical Biochemistry and Pediatrics, Hadassah University Hospital, Jerusalem; Laboratory of Genetics, National Institute of Mental Health and National Human Genome Research Institute, and Genome Technology Branch, National Human Genome Research Institute, and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda; Max-Delbrück-Centrum for Molecular Medicine, Berlin; and Department of Pediatrics, New York University Medical Center, New York
| | - Maire Leyne
- Molecular Neurogenetics Unit, Massachusetts General Hospital, Charlestown; Harvard Institute of Human Genetics, Harvard Medical School, Boston; Departments of Clinical Biochemistry and Pediatrics, Hadassah University Hospital, Jerusalem; Laboratory of Genetics, National Institute of Mental Health and National Human Genome Research Institute, and Genome Technology Branch, National Human Genome Research Institute, and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda; Max-Delbrück-Centrum for Molecular Medicine, Berlin; and Department of Pediatrics, New York University Medical Center, New York
| | - James Mull
- Molecular Neurogenetics Unit, Massachusetts General Hospital, Charlestown; Harvard Institute of Human Genetics, Harvard Medical School, Boston; Departments of Clinical Biochemistry and Pediatrics, Hadassah University Hospital, Jerusalem; Laboratory of Genetics, National Institute of Mental Health and National Human Genome Research Institute, and Genome Technology Branch, National Human Genome Research Institute, and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda; Max-Delbrück-Centrum for Molecular Medicine, Berlin; and Department of Pediatrics, New York University Medical Center, New York
| | - Math P. Cuajungco
- Molecular Neurogenetics Unit, Massachusetts General Hospital, Charlestown; Harvard Institute of Human Genetics, Harvard Medical School, Boston; Departments of Clinical Biochemistry and Pediatrics, Hadassah University Hospital, Jerusalem; Laboratory of Genetics, National Institute of Mental Health and National Human Genome Research Institute, and Genome Technology Branch, National Human Genome Research Institute, and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda; Max-Delbrück-Centrum for Molecular Medicine, Berlin; and Department of Pediatrics, New York University Medical Center, New York
| | - Christopher B. Liebert
- Molecular Neurogenetics Unit, Massachusetts General Hospital, Charlestown; Harvard Institute of Human Genetics, Harvard Medical School, Boston; Departments of Clinical Biochemistry and Pediatrics, Hadassah University Hospital, Jerusalem; Laboratory of Genetics, National Institute of Mental Health and National Human Genome Research Institute, and Genome Technology Branch, National Human Genome Research Institute, and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda; Max-Delbrück-Centrum for Molecular Medicine, Berlin; and Department of Pediatrics, New York University Medical Center, New York
| | - Brian Chadwick
- Molecular Neurogenetics Unit, Massachusetts General Hospital, Charlestown; Harvard Institute of Human Genetics, Harvard Medical School, Boston; Departments of Clinical Biochemistry and Pediatrics, Hadassah University Hospital, Jerusalem; Laboratory of Genetics, National Institute of Mental Health and National Human Genome Research Institute, and Genome Technology Branch, National Human Genome Research Institute, and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda; Max-Delbrück-Centrum for Molecular Medicine, Berlin; and Department of Pediatrics, New York University Medical Center, New York
| | - Maria Idelson
- Molecular Neurogenetics Unit, Massachusetts General Hospital, Charlestown; Harvard Institute of Human Genetics, Harvard Medical School, Boston; Departments of Clinical Biochemistry and Pediatrics, Hadassah University Hospital, Jerusalem; Laboratory of Genetics, National Institute of Mental Health and National Human Genome Research Institute, and Genome Technology Branch, National Human Genome Research Institute, and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda; Max-Delbrück-Centrum for Molecular Medicine, Berlin; and Department of Pediatrics, New York University Medical Center, New York
| | - Luba Reznik
- Molecular Neurogenetics Unit, Massachusetts General Hospital, Charlestown; Harvard Institute of Human Genetics, Harvard Medical School, Boston; Departments of Clinical Biochemistry and Pediatrics, Hadassah University Hospital, Jerusalem; Laboratory of Genetics, National Institute of Mental Health and National Human Genome Research Institute, and Genome Technology Branch, National Human Genome Research Institute, and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda; Max-Delbrück-Centrum for Molecular Medicine, Berlin; and Department of Pediatrics, New York University Medical Center, New York
| | - Christiane M. Robbins
- Molecular Neurogenetics Unit, Massachusetts General Hospital, Charlestown; Harvard Institute of Human Genetics, Harvard Medical School, Boston; Departments of Clinical Biochemistry and Pediatrics, Hadassah University Hospital, Jerusalem; Laboratory of Genetics, National Institute of Mental Health and National Human Genome Research Institute, and Genome Technology Branch, National Human Genome Research Institute, and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda; Max-Delbrück-Centrum for Molecular Medicine, Berlin; and Department of Pediatrics, New York University Medical Center, New York
| | - Izabela Makalowska
- Molecular Neurogenetics Unit, Massachusetts General Hospital, Charlestown; Harvard Institute of Human Genetics, Harvard Medical School, Boston; Departments of Clinical Biochemistry and Pediatrics, Hadassah University Hospital, Jerusalem; Laboratory of Genetics, National Institute of Mental Health and National Human Genome Research Institute, and Genome Technology Branch, National Human Genome Research Institute, and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda; Max-Delbrück-Centrum for Molecular Medicine, Berlin; and Department of Pediatrics, New York University Medical Center, New York
| | - Michael J. Brownstein
- Molecular Neurogenetics Unit, Massachusetts General Hospital, Charlestown; Harvard Institute of Human Genetics, Harvard Medical School, Boston; Departments of Clinical Biochemistry and Pediatrics, Hadassah University Hospital, Jerusalem; Laboratory of Genetics, National Institute of Mental Health and National Human Genome Research Institute, and Genome Technology Branch, National Human Genome Research Institute, and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda; Max-Delbrück-Centrum for Molecular Medicine, Berlin; and Department of Pediatrics, New York University Medical Center, New York
| | - Daniel Krappmann
- Molecular Neurogenetics Unit, Massachusetts General Hospital, Charlestown; Harvard Institute of Human Genetics, Harvard Medical School, Boston; Departments of Clinical Biochemistry and Pediatrics, Hadassah University Hospital, Jerusalem; Laboratory of Genetics, National Institute of Mental Health and National Human Genome Research Institute, and Genome Technology Branch, National Human Genome Research Institute, and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda; Max-Delbrück-Centrum for Molecular Medicine, Berlin; and Department of Pediatrics, New York University Medical Center, New York
| | - Claus Scheidereit
- Molecular Neurogenetics Unit, Massachusetts General Hospital, Charlestown; Harvard Institute of Human Genetics, Harvard Medical School, Boston; Departments of Clinical Biochemistry and Pediatrics, Hadassah University Hospital, Jerusalem; Laboratory of Genetics, National Institute of Mental Health and National Human Genome Research Institute, and Genome Technology Branch, National Human Genome Research Institute, and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda; Max-Delbrück-Centrum for Molecular Medicine, Berlin; and Department of Pediatrics, New York University Medical Center, New York
| | - Channa Maayan
- Molecular Neurogenetics Unit, Massachusetts General Hospital, Charlestown; Harvard Institute of Human Genetics, Harvard Medical School, Boston; Departments of Clinical Biochemistry and Pediatrics, Hadassah University Hospital, Jerusalem; Laboratory of Genetics, National Institute of Mental Health and National Human Genome Research Institute, and Genome Technology Branch, National Human Genome Research Institute, and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda; Max-Delbrück-Centrum for Molecular Medicine, Berlin; and Department of Pediatrics, New York University Medical Center, New York
| | - Felicia B. Axelrod
- Molecular Neurogenetics Unit, Massachusetts General Hospital, Charlestown; Harvard Institute of Human Genetics, Harvard Medical School, Boston; Departments of Clinical Biochemistry and Pediatrics, Hadassah University Hospital, Jerusalem; Laboratory of Genetics, National Institute of Mental Health and National Human Genome Research Institute, and Genome Technology Branch, National Human Genome Research Institute, and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda; Max-Delbrück-Centrum for Molecular Medicine, Berlin; and Department of Pediatrics, New York University Medical Center, New York
| | - James F. Gusella
- Molecular Neurogenetics Unit, Massachusetts General Hospital, Charlestown; Harvard Institute of Human Genetics, Harvard Medical School, Boston; Departments of Clinical Biochemistry and Pediatrics, Hadassah University Hospital, Jerusalem; Laboratory of Genetics, National Institute of Mental Health and National Human Genome Research Institute, and Genome Technology Branch, National Human Genome Research Institute, and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda; Max-Delbrück-Centrum for Molecular Medicine, Berlin; and Department of Pediatrics, New York University Medical Center, New York
| |
Collapse
|
25
|
Zhang JS, Wang L, Huang H, Nelson M, Smith DI. Keratin 23 (K23), a novel acidic keratin, is highly induced by histone deacetylase inhibitors during differentiation of pancreatic cancer cells. Genes Chromosomes Cancer 2001. [DOI: 10.1002/1098-2264(2000)9999:9999<::aid-gcc1070>3.0.co;2-w] [Citation(s) in RCA: 47] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
|
26
|
Porkka KP, Visakorpi T. Detection of differentially expressed genes in prostate cancer by combining suppression subtractive hybridization and cDNA library array. J Pathol 2001; 193:73-9. [PMID: 11169518 DOI: 10.1002/1096-9896(2000)9999:9999<::aid-path751>3.0.co;2-y] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Abstract
The molecular mechanisms underlying the development and progression of prostate cancer have remained poorly understood. The identification of differentially expressed genes has been used as a tool to recognize genes that are involved in disease processes. In this study we combined suppression subtractive hybridization (SSH) and cDNA array hybridization to identify genes whose expression is decreased in prostate cancer. cDNA from benign prostatic hyperplasia (BPH) was subtracted with cDNA from the prostate cancer cell line PC-3 and 386 of the subtracted clones were arrayed onto a nylon filter membrane. The differential gene expression was then verified by hybridizing the filter with radioactively labelled first-strand cDNA preparations from BPH, PC-3, four other cancer cell lines, and a normal prostate epithelial cell line (PrEC). In order to validate SSH and cDNA array hybridization, the enrichment of clones in the subtraction, as well as the sensitivity and linearity of array hybridization, was first evaluated. The array hydridization results were confirmed by northern analysis and selected clones were sequenced. Altogether, several known genes, such as prostate-specific antigen (PSA), human glandular kallikrein 2 (hK2), phosphatidic acid phosphatase type 2a (PAP2a), alpha-tropomyosin, and insulin-like growth factor binding protein 7 (IGFBP-7), as well as an anonymous transcript (EST), were found to be expressed less in PC-3 than in BPH. Further studies on the significance of these genes in the development of prostate cancer are now warranted.
Collapse
Affiliation(s)
- K P Porkka
- Laboratory of Cancer Genetics, Institute of Medical Technology, University of Tampere and Tampere University Hospital, Tampere, Finland
| | | |
Collapse
|
27
|
Janssens B, Staes K, van Roy F. Human alpha-catulin, a novel alpha-catenin-like molecule with conserved genomic structure, but deviating alternative splicing. BIOCHIMICA ET BIOPHYSICA ACTA 1999; 1447:341-7. [PMID: 10542337 DOI: 10.1016/s0167-4781(99)00170-0] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
A new human cDNA was cloned and termed alpha-catulin, based on sequence similarity with both alpha-CATenins and vincULIN. The mRNA is present ubiquitously, although low expression levels are found in neural tissues. The genomic organization of the alpha-catulin gene CTNNAL1 is closely related to that of the alphaE-catenin gene CTNNA1, but not at all to that of the vinculin gene. Alternative splicing of the last exon generates a frameshift, resulting in a truncated protein with a new carboxy-terminus.
Collapse
Affiliation(s)
- B Janssens
- Molecular Cell Biology Unit, Department of Molecular Biology, Flanders Interuniversity Institute for Biotechnology (VIB)-University of Ghent, B-9000, Ghent, Belgium
| | | | | |
Collapse
|